OncLive articleshttps://www.onclive.com/newsOncLive articles© 2026 MJH Life Sciences™ and OncLive. All rights reserved.Sun, 11 Oct 2026 10:24:37 +00005en-us14447https://www.onclive.com/newshttps://www.onclive.com/logo.webphttps://www.onclive.com/view/the-oncfive-top-oncology-articles-for-the-week-of-10-4-2026https://www.onclive.com/view/the-oncfive-top-oncology-articles-for-the-week-of-10-4-2026<![CDATA[The FDA approved atezolizumab plus chemo for stage III colon cancer, cleared a tucatinib-based maintenance regimen for advanced breast cancer, and more.]]>Sat, 10 Oct 2026 12:00:00 GMTOncLiveusOncLive Articleshttps://www.onclive.com/view/fda-flashback-hematologic-cancer-decisions-and-news-from-september-2026https://www.onclive.com/view/fda-flashback-hematologic-cancer-decisions-and-news-from-september-2026<![CDATA[Read a refresh of hematologic cancer FDA and global regulatory news from September 2026.]]>Sat, 10 Oct 2026 10:00:00 GMTOncLiveusOncLive Articleshttps://www.onclive.com/view/dr-sinicrope-on-the-fda-approval-of-atezolizumab-plus-chemo-for-colon-cancerhttps://www.onclive.com/view/dr-sinicrope-on-the-fda-approval-of-atezolizumab-plus-chemo-for-colon-cancer<![CDATA[Frank A. Sinicrope, MD, discusses the FDA approval of the ATOMIC trial regimen for patients with stage III dMMR colon cancer.]]>Sat, 10 Oct 2026 00:00:00 GMTOncLiveusOncLive Articleshttps://www.onclive.com/view/guardant360-cdx-receives-european-approval-as-companion-diagnostic-for-camizestrant-in-esr1-mutated-advanced-breast-cancerhttps://www.onclive.com/view/guardant360-cdx-receives-european-approval-as-companion-diagnostic-for-camizestrant-in-esr1-mutated-advanced-breast-cancer<![CDATA[The liquid biopsy identifies ESR1 mutations in blood to select patients with metastatic breast cancer who may be eligible for treatment with camizestrant.]]>Fri, 09 Oct 2026 21:30:00 GMTOncLiveusOncLive Articleshttps://www.onclive.com/view/navigating-patient-centric-treatment-administration-strategies-in-myelomahttps://www.onclive.com/view/navigating-patient-centric-treatment-administration-strategies-in-myeloma<![CDATA[Beth Faiman, PhD, MSN, APN-BC, AOCN, FAAN, FAPO, and Sikander Ailawadhi, MD, discuss how on-body administration methods are affecting myeloma management.]]>Fri, 09 Oct 2026 19:21:18 GMTOncLiveusOncLive Articleshttps://www.onclive.com/view/fda-grants-fast-track-designation-to-psv359-for-advanced-fap-positive-solitary-fibrous-tumorshttps://www.onclive.com/view/fda-grants-fast-track-designation-to-psv359-for-advanced-fap-positive-solitary-fibrous-tumors<![CDATA[The FDA granted fast track designation to PSV359 for locally advanced unresectable or metastatic FAP-positive solitary fibrous tumors.]]>Fri, 09 Oct 2026 18:10:30 GMTOncLiveusOncLive Articleshttps://www.onclive.com/view/targeted-approaches-in-pancreatic-cancer-chemo-intensification-in-crc-take-center-stage-as-key-gi-oncology-presentations-at-esmo-2026https://www.onclive.com/view/targeted-approaches-in-pancreatic-cancer-chemo-intensification-in-crc-take-center-stage-as-key-gi-oncology-presentations-at-esmo-2026<![CDATA[Experts spotlight the gastrointestinal cancer presentations they’re most excited to see at the 2026 ESMO Congress.]]>Fri, 09 Oct 2026 18:00:00 GMTOncLiveusOncLive Articleshttps://www.onclive.com/view/ucsf-health-reaches-25-000-robotic-surgerieshttps://www.onclive.com/view/ucsf-health-reaches-25-000-robotic-surgeries<![CDATA[Surgeons at the UC San Francisco have performed over 25,000 robotically assisted minimally invasive surgeries.]]>Fri, 09 Oct 2026 16:00:00 GMTOncLiveusOncLive Articleshttps://www.onclive.com/view/fda-grants-breakthrough-device-designation-to-natera-s-multi-cancer-early-detection-assayhttps://www.onclive.com/view/fda-grants-breakthrough-device-designation-to-natera-s-multi-cancer-early-detection-assay<![CDATA[Natera’s blood-based, cell-free DNA multi-cancer early detection assay received the designation after the FDA reviewed data spanning 12 cancer types.]]>Fri, 09 Oct 2026 15:08:59 GMTOncLiveusOncLive Articleshttps://www.onclive.com/view/next-generation-nampt-inhibitors-aim-to-revive-a-stalled-target-in-aml-and-mdshttps://www.onclive.com/view/next-generation-nampt-inhibitors-aim-to-revive-a-stalled-target-in-aml-and-mds<![CDATA[Novel NAMPT inhibitors may circumvent the limited tolerability of previously studied agents and improve treatment outcomes in AML and MDS. ]]>Fri, 09 Oct 2026 14:00:00 GMTOncLiveusOncLive Articleshttps://www.onclive.com/view/met-as-an-actionable-resistance-mechanism-new-randomized-data-and-what-it-meanshttps://www.onclive.com/view/met-as-an-actionable-resistance-mechanism-new-randomized-data-and-what-it-means<![CDATA[In this segment, the panel focuses on MET alterations as one of the most consistently actionable resistance mechanisms in EGFR-mutant non-small cell lung cancer and discusses the first randomized trial data now available in this setting.]]>Fri, 09 Oct 2026 12:05:00 GMTOncLiveusOncLive Articleshttps://www.onclive.com/view/onclive-weekly-news-quiz-10-9-2026-did-you-miss-crucial-colon-cancer-myeloma-breast-cancer-and-lung-cancer-updates-https://www.onclive.com/view/onclive-weekly-news-quiz-10-9-2026-did-you-miss-crucial-colon-cancer-myeloma-breast-cancer-and-lung-cancer-updates-<![CDATA[Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.]]>Fri, 09 Oct 2026 12:00:00 GMTOncLiveusOncLive Articleshttps://www.onclive.com/view/progressing-on-frontline-therapy-resistance-mechanisms-and-second-line-optionshttps://www.onclive.com/view/progressing-on-frontline-therapy-resistance-mechanisms-and-second-line-options<![CDATA[In this segment, the panel addresses what happens when a patient progresses on frontline EGFR-directed therapy, starting with how to approach repeat molecular profiling and what resistance mechanisms to look for.]]>Fri, 09 Oct 2026 12:00:00 GMTOncLiveusOncLive Articleshttps://www.onclive.com/view/dr-hamilton-on-maintenance-tucatinib-based-therapy-for-her2-breast-cancerhttps://www.onclive.com/view/dr-hamilton-on-maintenance-tucatinib-based-therapy-for-her2-breast-cancer<![CDATA[Erika P. Hamilton, MD, discusses how the FDA approval of tucatinib-based first-line maintenance fits into HER2-positive breast cancer care.]]>Fri, 09 Oct 2026 00:00:00 GMTOncLiveusOncLive Articleshttps://www.onclive.com/view/maverick-b7-h3-directed-adcs-and-adaura-data-headline-key-lung-cancer-findings-from-wclc-2026https://www.onclive.com/view/maverick-b7-h3-directed-adcs-and-adaura-data-headline-key-lung-cancer-findings-from-wclc-2026<![CDATA[Experts break down key lung cancer data and trends from the IASLC 2026 World Conference on Lung Cancer.]]>Thu, 08 Oct 2026 20:32:00 GMTOncLiveusOncLive Articleshttps://www.onclive.com/view/dr-chae-on-the-differences-between-tumor-informed-and-tissue-agnostic-assays-in-nsclchttps://www.onclive.com/view/dr-chae-on-the-differences-between-tumor-informed-and-tissue-agnostic-assays-in-nsclc<![CDATA[Young Kwang Chae, MD, discusses tumor-informed and tissue-agnostic ctDNA MRD assays in postsurgical lung cancer surveillance.]]>Thu, 08 Oct 2026 18:45:00 GMTOncLiveusOncLive Articleshttps://www.onclive.com/view/fda-approves-atezolizumab-plus-chemo-for-stage-iii-dmmr-colon-cancerhttps://www.onclive.com/view/fda-approves-atezolizumab-plus-chemo-for-stage-iii-dmmr-colon-cancer<![CDATA[The FDA approved atezolizumab plus chemotherapy for the adjuvant treatment of stage III mismatch repair–deficient colon cancer.]]>Thu, 08 Oct 2026 17:50:49 GMTOncLiveusOncLive Articleshttps://www.onclive.com/view/vir-5500-receives-fda-fast-track-designation-in-mcrpchttps://www.onclive.com/view/vir-5500-receives-fda-fast-track-designation-in-mcrpc<![CDATA[The FDA granted fast track designation to the PSMA-targeted T-cell engager VIR-5500 for late-line metastatic castration-resistant prostate cancer.]]>Thu, 08 Oct 2026 17:15:51 GMTOncLiveusOncLive Articleshttps://www.onclive.com/view/new-statewide-plan-aims-to-eliminate-cervical-cancer-in-texas-by-2032https://www.onclive.com/view/new-statewide-plan-aims-to-eliminate-cervical-cancer-in-texas-by-2032<![CDATA[MD Anderson Cancer Center announced the Texas Lone Star Cervical Cancer Elimination Plan 2027-2032, a 5-year roadmap to eliminate cervical cancer in Texas.]]>Thu, 08 Oct 2026 16:00:00 GMTOncLiveusOncLive Articleshttps://www.onclive.com/view/china-s-nmpa-approves-dato-dxd-for-metastatic-tnbc-ineligible-for-pd--l-1-inhibitionhttps://www.onclive.com/view/china-s-nmpa-approves-dato-dxd-for-metastatic-tnbc-ineligible-for-pd--l-1-inhibition<![CDATA[China's approval of Dato-DXd for TNBC was supported by TROPION-Breast02 data showing a median OS of 23.7 months vs 18.7 months with chemotherapy.]]>Thu, 08 Oct 2026 15:57:14 GMTOncLiveusOncLive Articleshttps://www.onclive.com/view/iberdomide-plus-daratumumab-dexamethasone-yields-significant-pfs-benefit-in-r-r-myelomahttps://www.onclive.com/view/iberdomide-plus-daratumumab-dexamethasone-yields-significant-pfs-benefit-in-r-r-myeloma<![CDATA[Iberdomide plus daratumumab/dexamethasone improved PFS vs DVd in relapsed/refractory multiple myeloma, meeting a dual primary end point of EXCALIBER-RRMM.]]>Thu, 08 Oct 2026 15:29:12 GMTOncLiveusOncLive Articleshttps://www.onclive.com/view/china-s-nmpa-approves-adjuvant-t-dxd-for-her2-early-breast-cancer-with-residual-invasive-diseasehttps://www.onclive.com/view/china-s-nmpa-approves-adjuvant-t-dxd-for-her2-early-breast-cancer-with-residual-invasive-disease<![CDATA[The NMPA approved T-DXd after neoadjuvant therapy, based on DESTINY-Breast05 data, in which the agent lowered the risk of recurrence or death vs T-DM1.]]>Thu, 08 Oct 2026 15:00:00 GMTOncLiveusOncLive Articleshttps://www.onclive.com/view/breast-cancer-monthly-rewind-key-news-and-expert-insights-you-may-have-missed-in-september-2026https://www.onclive.com/view/breast-cancer-monthly-rewind-key-news-and-expert-insights-you-may-have-missed-in-september-2026<![CDATA[Check out this September recap of OncLive’s coverage of the top news and expert insights in breast cancer.]]>Thu, 08 Oct 2026 13:00:00 GMTOncLiveusOncLive Articleshttps://www.onclive.com/view/individualized-neoantigen-vaccine-elicits-durable-t-cell-responses-in-resected-hpv-hnscchttps://www.onclive.com/view/individualized-neoantigen-vaccine-elicits-durable-t-cell-responses-in-resected-hpv-hnscc<![CDATA[Adjuvant TG4050 was well tolerated and generated long-lasting neoantigen-specific T-cell responses in resected HPV-negative HNSCC.]]>Thu, 08 Oct 2026 12:00:00 GMTOncLiveusOncLive Articleshttps://www.onclive.com/view/nonrelapse-mortality-safety-and-long-term-trajectory-after-gvhd-controlhttps://www.onclive.com/view/nonrelapse-mortality-safety-and-long-term-trajectory-after-gvhd-control<![CDATA[Rawan Faramand, MD, says the finding that stands out most from newer approaches is the nonrelapse mortality of about 3% reported in the Precision-T trial, which compares favorably with historical rates of 15% to 20%, particularly in the myeloablative setting.]]>Thu, 08 Oct 2026 12:00:00 GMTOncLiveusOncLive Articleshttps://www.onclive.com/view/novel-mek-inhibitor-research-aims-to-balance-efficacy-and-tolerability-in-pancreatic-cancerhttps://www.onclive.com/view/novel-mek-inhibitor-research-aims-to-balance-efficacy-and-tolerability-in-pancreatic-cancer<![CDATA[Dr Chung discusses the development of atebimetinib in metastatic pancreatic cancer. ]]>Wed, 07 Oct 2026 22:00:00 GMTOncLiveusOncLive Articleshttps://www.onclive.com/view/september-roundup-of-fda-approvals-in-oncology-8-decisions-to-knowhttps://www.onclive.com/view/september-roundup-of-fda-approvals-in-oncology-8-decisions-to-know<![CDATA[Here is your cheat sheet to all therapeutic options that were cleared by the FDA in September 2026 spanning tumor types.]]>Wed, 07 Oct 2026 19:47:34 GMTOncLiveusOncLive Articleshttps://www.onclive.com/view/fda-approves-tucatinib-plus-trastuzumab-pertuzumab-as-first-line-maintenance-in-advanced-her2-breast-cancerhttps://www.onclive.com/view/fda-approves-tucatinib-plus-trastuzumab-pertuzumab-as-first-line-maintenance-in-advanced-her2-breast-cancer<![CDATA[The FDA approved tucatinib plus trastuzumab and pertuzumab as maintenance for advanced HER2-positive breast cancer after induction.]]>Wed, 07 Oct 2026 17:16:59 GMTOncLiveusOncLive Articleshttps://www.onclive.com/view/fda-grants-breakthrough-therapy-designation-to-temab-a-in-previously-treated-c-met-expressing-nonsquamous-nsclchttps://www.onclive.com/view/fda-grants-breakthrough-therapy-designation-to-temab-a-in-previously-treated-c-met-expressing-nonsquamous-nsclc<![CDATA[The c-Met–directed ADC was designated for EGFR wild-type nonsquamous NSCLC after platinum chemotherapy and anti–PD-(L)1 therapy.]]>Wed, 07 Oct 2026 16:25:00 GMTOncLiveusOncLive Articleshttps://www.onclive.com/view/two-dana-farber-researchers-receive-prestigious-new-innovator-award-from-the-national-institutes-of-healthhttps://www.onclive.com/view/two-dana-farber-researchers-receive-prestigious-new-innovator-award-from-the-national-institutes-of-health<![CDATA[Dana-Farber’s Xin Gu, PhD, and Nicholas Polizzi, PhD, received NIH New Innovator Awards for high-risk, high-reward research.]]>Wed, 07 Oct 2026 16:00:00 GMTOncLiveusOncLive Articles